Using hyperspectral imaging to improve surgery for low grade glioma
Validation of Label-free, Wide-field, Real-time Intra-operative Tissue Discrimination and Tumor Detection of Low Grade Glioma Using a Hyperspectral Imaging (HSI) Sensor/camera Integrated in the Operative Microscope
This study is testing whether a special imaging technology can help doctors remove low grade gliomas more effectively during surgery by clearly showing the difference between tumor and normal brain tissue.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 10 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Universitaire Ziekenhuizen KU Leuven Academic / other |
| Locations | 1 site (Leuven, Vlaams-Brabant) |
| Trial ID | NCT04859725 on ClinicalTrials.gov |
What this trial studies
This study aims to enhance the surgical resection of low grade gliomas by utilizing hyperspectral imaging (HSI) technology. Patients scheduled for tumor resection will have HSI data collected before, during, and after the procedure to help distinguish tumor tissue from normal brain tissue in real-time. The data will be analyzed using machine learning techniques to identify reliable patterns that can guide surgical decision-making. This innovative approach seeks to improve the extent of tumor removal and potentially lead to better patient outcomes.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older who have a radiologically suspected low grade glioma and are scheduled for tumor resection.
Not a fit: Patients under 18 years old or those whose final pathology reveals a diagnosis other than low grade glioma will not benefit from this study.
Why it matters
Potential benefit: If successful, this technology could significantly improve surgical outcomes for patients with low grade glioma by enabling more precise tumor resections.
How similar studies have performed: While the use of hyperspectral imaging in surgical settings is emerging, this specific application for low grade glioma is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years * Radiologically suspected low grade glioma (newly diagnosed or recurrent) * Scheduled for tumor resection at UZ Leuven * Signed informed consent document prior to resection Exclusion Criteria: * Children with age \< 18 years * If final pathology reveals other pathological diagnosis than low grade glioma, datacubes will not be included in the final analysis
Where this trial is running
Leuven, Vlaams-Brabant
- UZ Leuven — Leuven, Vlaams-Brabant, Belgium (Recruiting)
Study contacts
- Principal investigator: Steven De Vleeschouwer, MD, PhD — UZ Leuven
- Study coordinator: Steven De Vleeschouwer, MD, PhD
- Email: neurochirurgie@uzleuven.be
- Phone: +3216344290
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.